Skip to content


Imatinib, a potent medication belonging to the Tyrosine Kinase Inhibitor class, effectively blocks several key proteins involved in cancer progression, including BCR-ABL, PDGFR, and c-Kit. By specifically targeting these proteins, Imatinib disrupts the signaling pathways necessary for abnormal cell proliferation and survival. Additionally, Imatinib competes with ATP (Adenosine triphosphate) by binding to the ATP-binding pocket of these proteins, preventing ATP from activating them. This inhibition prevents tumor growth and spread, making Imatinib a crucial therapy in the treatment of certain leukemias and other cancers.